A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Effects on Arterial Structure and Function of ACZ885 in Patients With Intermittent Claudication

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Effects on Arterial Structure and Function of ACZ885 in Patients With Intermittent Claudication

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Atherosclerosis
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 21 Jul 2017 Status changed to discontinued based on result from primary endpoint analysis
    • 21 Nov 2016 Status changed from recruiting to completed.
    • 17 Nov 2016 This trial was discontinued in Germany, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top